A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

NCT07668388 · Not yet recruiting

Last updated 2026-07-12

This study tests different doses of the medicine UBT251 to see how well it lowers blood sugar in adults with type 2 diabetes.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 300 people Planned (estimated).

Who can join Ages 18–75 · all sexes

Timeline Started 2026-06 · est. completion 2027-11

Where 69 sites · Australia, Germany, Hungary, Poland, Romania, Slovakia, South Korea, Spain, United States

What this study is testing ClinicalTrials.gov NCT07668388 ↗

Description as written by the study sponsor.

The study is testing UBT251 in participants with type 2 diabetes. The purpose of this clinical study is to find out if UBT251 is effective and safe for treating participants with type 2 diabetes. Participants will either get UBT251, UBT251 placebo, semaglutide, or semaglutide placebo. Which treatment participants get is decided by chance. UBT251 is the treatment being tested and is not yet available for doctors to prescribe, while semaglutide is a medicine used to treat type 2 diabetes that doctors can already prescribe.

Treatments tested

UBT251 Drug

UBT251 will be administered subcutaneously once-weekly.
UBT251 Placebo Drug

UBT251 placebo will be administered subcutaneously once-weekly.
Semaglutide Drug

Semaglutide will be administered subcutaneously once-weekly.
Semaglutide Placebo Drug

Semaglutide placebo will be administered subcutaneously once-weekly.

Main thing measured	UBT251: Change in glycated haemoglobin (HbA1c)
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07668388 ↗